Supplementary Tables from Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers

Supplementary Tables - PDF file 33K, Supplementary Table 1. Dose levels, dose administered on each treatment day, days 1,3, and 5 of a 21-day cycle, and number of patients treated on each dose level. Supplementary Table 2. Romidepsin toxicities found in 9 patients enrolled at 9 mg/m2 during cycle 1 or in all cycles following treatment at 9 mg/m2. Supplementary Table 3. Cycle 1, Day 1 Romidepsin pharmacokinetic parameters (Mean plus-minus SD). Supplementary Table 4. ECG ST and T wave changes as pharmacodynamic marker